Inhibikase Therapeutics, Inc.
Assets & Liabilities
| Period | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| Dec 2019 | — | — | $18.5K |
| Mar 2020 | — | — | $13.1K |
| Jun 2020 | — | — | $7.8K |
| Sep 2020 | — | — | $16.2K |
| Dec 2020 | $5.0M | $14.8M | $14.0M |
| Mar 2021 | $3.8M | $11.9M | $9.6M |
| Jun 2021 | $2.2M | $49.2M | $46.8M |
| Sep 2021 | $2.7M | $45.9M | $44.8M |
| Dec 2021 | $4.1M | $42.5M | $40.8M |
| Mar 2022 | $4.4M | $38.4M | $36.6M |
| Jun 2022 | $4.5M | $34.0M | $32.2M |
| Sep 2022 | $3.4M | $28.6M | $5.8M |
| Dec 2022 | $3.9M | $24.9M | $7.2M |
| Mar 2023 | $2.8M | $28.2M | $4.0M |
| Jun 2023 | $2.9M | $22.3M | $1.9M |
| Sep 2023 | $2.9M | $17.9M | $14.9M |
| Dec 2023 | $3.5M | $14.5M | $9.2M |
| Mar 2024 | $4.3M | $11.1M | $2.4M |
| Jun 2024 | $3.7M | $8.8M | $3.1M |
| Sep 2024 | $4.9M | $4.4M | $913.4K |
| Dec 2024 | $3.7M | $98.6M | $97.5M |
| Mar 2025 | $8.6M | $94.3M | $73.4M |
| Jun 2025 | $8.8M | $88.9M | $77.7M |
| Sep 2025 | $6.7M | $79.6M | $38.3M |
| Dec 2025 | $8.3M | $181.2M | $178.8M |
| Mar 2026 | $5.7M | $173.3M | $49.6M |
| Jun 2026 | $10.3M | $163.6M | $31.2M |